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Abstract
Previous studies have shown that the small molecule iron transport inhibitor ferristatin (NSC30611) acts by down-regulating
transferrin receptor-1 (TfR1) via receptor degradation. In this investigation, we show that another small molecule, ferristatin
II (NSC8679), acts in a similar manner to degrade the receptor through a nystatin-sensitive lipid raft pathway. Structural
domains of the receptor necessary for interactions with the clathrin pathway do not appear to be necessary for ferristatin II
induced degradation of TfR1. While TfR1 constitutively traffics through clathrin-mediated endocytosis, with or without
ligand, the presence of Tf blocked ferristatin II induced degradation of TfR1. This effect of Tf was lost in a ligand binding
receptor mutant G647A TfR1, suggesting that Tf binding to its receptor interferes with the drug’s activity. Rats treated with
ferristatin II have lower TfR1 in liver. These effects are associated with reduced intestinal 59Fe uptake, lower serum iron and
transferrin saturation, but no change in liver non-heme iron stores. The observed hypoferremia promoted by degradation of
TfR1 by ferristatin II appears to be due to induced hepcidin gene expression.
Citation: Byrne SL, Buckett PD, Kim J, Luo F, Sanford J, et al. (2013) Ferristatin II Promotes Degradation of Transferrin Receptor-1 In Vitro and In Vivo. PLoS
ONE 8(7): e70199. doi:10.1371/journal.pone.0070199
Editor: Makoto Kanzaki, Tohoku University, Japan
Received May 6, 2013; Accepted June 14, 2013; Published July 23, 2013
Copyright:  2013 Byrne et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The research reported in this publication was supported by the National Institute of Diabetes, Digestive and Kidney Diseases of the National Institutes
of Health under award numbers R01DK046750 and RC1DK086744 to MW-R and award number R37DK054488 to CAE. SLB was supported by the National Institute
of Environmental Health Sciences of the National Institutes of Health under award number T32ES016645. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: wessling@hsph.harvard.edu
. These authors contributed equally to this work.
Introduction
Iron is involved in various processes of cellular homeostasis
including DNA synthesis and repair, ATP synthesis, and oxygen
transport [1]. It is essential for life and depletion of iron restricts
growth of cells [2,3,4]. Iron is absorbed from the diet by duodenal
enterocytes and is transported to the periphery bound to
transferrin (Tf). At neutral pH, holo-Tf binds to receptors on the
cell surface [5]. This complex undergoes clathrin-dependent
endocytosis and is delivered to early endosomes [6]. Within the
low pH environment of the endosome, iron is released from Tf.
Iron is reduced from ferric iron (Fe3+) to ferrous iron (Fe2+) by the
ferrireductase Steap3 [7,8]. Ferrous iron is then transported into
the cytosol via divalent metal transporter-1 (DMT-1) [9], ZIP14
[10] and/or TRPML [11]. The ligand-receptor complex, devoid
of iron, is recycled back to the plasma membrane where apo-Tf
dissociates and continues the cycle of iron acquisition and delivery
to peripheral tissues [12,13].
There are two known Tf receptors, TfR1 and TfR2. At the
cellular level, TfR1 is ubiquitously expressed and is largely
responsible for Tf-mediated delivery of iron to peripheral tissues
[14]. TfR1 is a constitutively recycling receptor that undergoes
clathrin-mediated endocytosis with or without its ligand [12,15]. It
is widely held that the presence of TfR1 identifies the endocytic,
sorting and recycling compartments of most cells. Often marked
by fluorescently labeled Tf or receptor immunoreactivity, TfR1 is
frequently used as a reference marker for these domains [16,17].
The interactions of TfR1 with the clathrin machinery also provide
a paradigm for how membrane proteins engage with coated pits
and become internalized by coated vesicles [18]. In particular,
receptor interactions with the clathrin adaptor protein AP-2 have
been studied at the molecular and structural level [19,20,21]. At
the plasma membrane, interactions with the AP-2 adaptor
complex mediate assembly of clathrin triskelions that form a
budding coated pit that is pinched off by dynamin to generate a
coated vesicle [22,23].
At the systemic level, regulation of iron homeostasis has been
elucidated through studies of hereditary hemochromatosis [24].
Mutations in HFE [25], transferrin receptor-2 [26], ferroportin
[27], hepcidin [28], or hemojuvelin [29] have been identified in
different forms of human disease. Iron metabolism is regulated
through a complex network of protein-protein interactions
between these factors. Although TfR1 is ubiquitously expressed
and plays a key role in iron delivery through receptor-mediated
endocytosis of diferric transferrin, HFE and TfR2 play a more
specialized role in the liver where they have been shown to act as
upstream regulators of hepcidin synthesis [30]. A model has been
proposed wherein HFE interactions with TfR1 limit its association
with TfR2 [31]. When iron levels increase, saturation of Tf
promotes receptor binding, which in turn competitively displaces
HFE from TfR1 to allow its interaction with TfR2 [32]. Over-
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expression of HFE in the livers of mice increases hepcidin
expression, supporting the notion that levels of endogenous protein
are limiting [30,33].
Hepcidin, a 25 amino acid peptide hormone, is secreted
primarily by the liver and regulates systemic iron status [34]. The
peptide binds to the iron exporter ferroportin (Slc40a1), inducing
its internalization and lysosomal degradation [35]. This mecha-
nism controls intestinal iron efflux and recycling of iron from
macrophages [36,37]. Concordantly, hepcidin synthesis increases
with iron loading and decreases with iron deficiency [38,39].
Hepcidin levels are inappropriately low in hemochromatosis
patients with mutations in HFE [40] and TfR2 [41].
Genetic approaches to understanding iron homeostasis have
been complemented by the recent development of pharmacolog-
ical tools to either inhibit or activate transport and regulatory
factors involved in iron metabolism [42]. One approach to further
our understanding of the regulation of iron transport and
homeostasis at the molecular level is through the use of small
molecule inhibitors. Using a cell-based fluorescence screening
strategy, ferristatin (NSC306711) was initially identified as an
inhibitor of Tf-mediated iron delivery [43]. Characterization of
ferristatin’s action revealed that it promoted the degradation of
TfR1 in a nystatin-sensitive fashion. Internalization and receptor
down-regulation of TfR1 in the presence of ferristatin occurred in
a clathrin- and dynamin-independent manner [44]. These results
were unexpected given the established role of clathrin-mediated
endocytosis in TfR1 membrane trafficking, but were specific to
this receptor since ferristatin did not alter LDL receptor trafficking
[44]. More recently, NSC8679 (referred to here as ferristatin II)
was identified as a polysulphonated dye not only structurally
related to ferristatin but with functional similarities as well [45].
This investigation was undertaken to characterize ferristatin II
action and the nature of the nystatin-sensitive clathrin-indepen-
dent mechanism for TfR1 down-regulation. The alternative lipid
raft mediated trafficking and degradation pathway revealed by the
ferristatins may hold clinical potential to limit iron acquisition.
This idea is supported by results of in vivo experiments that reveal a
systemic effect on iron metabolism upon treatment with ferristatin
II.
Materials and Methods
Ethics Statement
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Harvard Medical Area Animal Care
and Use Committee (Animal Experimentation Protocol AEP
#04692).
Cell Culture
HeLa cells were grown in Dulbecco’s minimal essential medium
(DMEM) containing 50 U/mL penicillin, 50 mg/mL streptomy-
cin, L-glutamine, and 10% fetal bovine serum (FBS, Sigma).
TRVb cells [46] (a kind gift of Dr. Timothy E. McGraw, Weill
Medical College, Cornell University) were grown in Ham’s F-12
medium containing 10% FBS. Stably transfected TRVb cells
containing either WT TfR1, Y20C/F23A TfR1 or D3–28 TfR1
were grown in Ham’s F-12 containing 5 g/L glucose, 400 mg/mL
G418 and 5% FBS. Hep3B cells stably expressing human TfR2
[47] were maintained in minimal essential medium (MEM)
containing 1 mM sodium pyruvate, 0.1 mM non-essential amino
acids, 10% FBS and 400 mg/mL G418.
Ferristatin II Treatment: In vitro
Ferristatin II (NSC8679) was obtained from Sigma (Product No.
C1144, also called Chlorazol Black or Direct Black 38). For
treatment with ferristatin II, cells were first washed three times
with phosphate-buffered saline containing 1 mM MgCl2 and
0.1 mM CaCl2 (PBS
++) and then washed once with serum-free
medium. Fifty mM ferristatin II or DMSO control was added to
cells in serum free medium. To inhibit lysosomal degradation of
TfR1, cells were treated overnight with 10 nM Bafilomycin A1
(Sigma, B1793). To disrupt lipid rafts, cells were pretreated for 20
minutes with 25 mg/mL nystatin (Sigma) before addition of
ferristatin II. Cells were incubated at 37uC with 5% CO2 for 4
hours unless otherwise stated.
Ferristatin II Treatment: In vivo
Male Sprague-Dawley rats (3-wk-old) were injected twice daily
for 1 or 3 days with ferristatin II (up to maximum of 40 mg/kg) or
saline as a vehicle control. On day 2 or day 4, rats were injected
once and fasted for 6 hours. At the start of the fasting period, rats
were housed in metabolic cages for 6 h to collect urine. For 59Fe
tracer studies, on day 4 rats were fasted for 4 h prior to
administration of 59Fe by gavage (1 ml/g body weight of a solution
of 30 mCi/ml, diluted in 20 mM Tris, 150 mM NaCl, pH 5.7
with 10 mM freshly dissolved ascorbate). Blood samples were
taken at intervals from 15 min to 1 h and radioactivity was
determined by gamma counting. At the end of the study, rats were
euthanized by isoflurane overdose followed by exsanguination for
collection of tissues to analyze iron status.
Western Blot Analysis
After incubation with ferristatin II as described above, cells were
washed three times with ice cold PBS++ and lysed in NET lysis
buffer (150 mM NaCl, 5 mM EDTA, 10 mM Tris pH 7.4 and
1% Triton X-100) containing protease inhibitors (Protease
Inhibitor Set lll, Calbiochem) for 20 minutes on ice. Lysates were
cleared at 16,0006g for 10 minutes at 4uC and 20–60 mg of the
supernatant were loaded on 8% SDS-polyacrylamide gels. Livers
from rats treated with ferristatin ll or vehicle control were
homogenized in RIPA buffer (10 mM Tris, pH 7.4, 150 mM
NaCl, 1.0 mM EDTA, 0.1% SDS, 1.0% Triton X-100, 1.0%
sodium deoxycholate) containing protease inhibitors (Halt,
Thermo Scientific) and 100 mg samples were electrophoresed on
10% SDS-polyacrylamide gels. After electrophoresis, samples were
transferred to nitrocellulose or PVDF membrane, blocked with 5%
non-fat milk and immunoblotted using monoclonal mouse anti-
TfR1 antibody H68.4 (1:500 or 1:1000, Invitrogen), sheep anti-
TfR1 antibody (1:5000, [48]) monoclonal mouse anti-TfR2
antibody 9F81C11 (1:1000, Santa Cruz Biotechnology) or mouse
anti-Flag (1:1000, Sigma). As a loading control, blots were probed
with mouse anti-actin C4 clone (1:10,000, MP Biomedicals) or
mouse anti-tubulin (1:10,000, Sigma). Secondary antibody,
IRDye800 or IRDye680 conjugated donkey anti-mouse, donkey
anti-rabbit or donkey anti-sheep (1:10,000, LI-COR) was used to
detect immunoreactivity using an Odyssey Infrared Imaging
System (LI-COR). Relative intensities of protein bands were
normalized to actin using Odyssey version 2.1 software.
G647A TfR1 Mutagenesis and Transfection Experiments
The pcDNA3/G647A TfR1 plasmid was generated using
QuikChange XL site-directed mutagenesis (Strategene, La Jolla,
CA) using a template of pcDNA3/TfR1 and primers of 5’- CTG
TAT TCT GCT CGT GCA GAC TTC TTC CGT GC -3’ and
5’- GCA CGG AAG AAG TCT GCA CGA GCA GAA TAC AG
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-3’ following manufacturer’s instructions. TRVb cells were
transiently transfected to express either wild type TfR1 (2 mg
plasmid DNA) or the G647A TfR1 point mutant (2 mg plasmid
DNA) using LipofectAMINE2000 (Invitrogen) according to
manufacturer’s instructions. Cells were split 24 hours post-
transfection into 6-well plates and treated with ferristatin II the
following day. HeLa cells were transfected with HFE containing a
Flag tag (0.5 mg plasmid DNA) or pcDNA vector control (0.5 mg
plasmid DNA) as described above.
125I-Transferrin Surface Binding
TRVb cells were grown to 90% confluency in Ham’s F-12
medium containing 10% FBS. Cells were transfected as described
above with WT TfR1 or G647A TfR1. After 24 hours, cells were
plated into 6 well dishes and incubated for an additional 24 hours.
Cells were chilled on ice for 15 min and washed twice in ice-cold
serum-free Ham’s F-12 medium. Cell monolayers were incubated
on ice in serum-free Ham’s F-12 medium containing 20 mM
Hepes, pH 7.4, 2 mg/ml ovalbumin, and 500 nM 125I-Tf with or
without 5 mM unlabeled Tf to displace non-specifically bound
ligand. After incubation on ice for 2 hours, cells were washed 4
times with PBS++ and lysed with solubilization buffer (0.1% Triton
X-100, 0.1% NaOH). Cell-associated radioactivity was measured
by gamma counting. Data were adjusted to protein levels
determined by Bradford assay.
Fluorescence Microscopy
TRVb cells transfected with WT TfR1 or G647A TfR1 were
plated onto poly-L-Lysine coated cover slips 24 hours post
transfection and incubated for an additional 24 hours at 37uC,
5% CO2. Cells were washed with PBS
++ and fixed with 4%
paraformaldehyde. Cells were incubated with PBS (non-permea-
bilized) or PBS +0.1% Triton X-100 (permeabilized), washed with
1% NH4Cl and blocked with 5% goat serum. The cells were then
immunoreacted with mouse anti-human transferrin receptor,
OKT9 (eBioscience), followed by goat anti-mouse Alexa 488
(Invitrogen). Cells were imaged using a Zeiss Observer Z1
Axioscope microscope.
RNA Isolation, cDNA Synthesis and Quantitative PCR
Total RNA was isolated using TRIZOL reagent (Invitrogen)
according to the manufacturer’s instructions. An additional step
with Phenol/Chloroform/8-Quinolinol was used to further purify
the RNA. Five mg RNA were reverse transcribed using Super-
Script lll First-Strand Synthesis System (Invitrogen) using random
hexamers and oligo(dt)20 primers. Gene expression was analyzed
by quantitative real-time PCR using Power SYBR Green PCR
Master Mix (Applied Biosystems) on an Applied Biosystems 7300
Real Time PCR System. The cDNA was diluted 1:40 and 6 ml was
used as template in a 15 ml reaction volume. The conditions used
were: 40 cycles 95uC for 15 s, 55uC for 30 s, and 72uC for 30 s.
Analysis was performed in triplicate for each sample. A
dissociation curve analysis was performed to detect non-specific
products. 36B4 was used as a reference gene. All primers were
used at a final concentration of 200 nM. The primers used were:
hepcidin 5’-TGACAGTGCGCTGCTGATG-3’ (forward), 5’-
GGAATTCTTACAGCATTTACAGCAGA-3’ (reverse); 36B4
5’-AGATGCAGCAGATCCGCAT-3’ (forward) and 5’-
GTTCTTGCCCATCAGCACC-3’ (reverse). Calculations for
relative quantification were done using the comparative CT
method (DDCT).
Urinary Monoacetylbenzidine Determination
Rat urine was centrifuged, reduced with ascorbic acid at 1 mg/
ml, acidified to pH #3.0 using concentrated HCl and bound to a
Strata-X-C SPE column (Phenomenex). After washing, the sample
was eluted with 5% ammonium hydroxide in methanol, concen-
trated in a speedvac and analyzed using HPLC with a Zorbax
Eclipse Plus Phenyl-Hexyl column (Agilent Technologies). The
mobile phase was a step gradient starting with 95% 10 mM
ammonium acetate, pH 4.7 and 5% acetonitrile; reaching 35%
ammonium acetate, 65% acetonitrile after 15.5 mins. A flow rate
of 1 ml/min and a detection wavelength of 290 nm were used.
Fractions corresponding to the monoacetylbenzidine (MAB)
elution time were collected from a standard, control and ferristatin
ll treated urine samples and further analyzed by LCMS (The
Small Molecule Mass Spectrometry Facility at the FAS Center for
Systems Biology, Harvard University), confirming the peak
corresponded to the molecular mass of MAB.
Other Assays
Urinary creatinine was determined using the Creatinine
Reagent Set (Pointe Scientific Inc.) using a modification of the
manufacturer’s instructions. The working reagent (100 ml) was
added to urine samples or a serial dilution of a creatinine standard
(5 ml). After incubation at room temperature for 20 mins, the OD
was read at 510 nm. These values were used to normalize urinary
MAB levels. Serum alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) levels were determined using Infinity ALT
and AST reagents (Thermo Scientific) according to the manufac-
turer’s instructions. Assays for hematocrit and liver non-heme iron
concentrations were performed as previously described [49].
Serum iron levels were determined as described [50].
Results
Ferristatin II Induces Degradation of TfR1
Previous screening of the National Cancer Institute’s small
molecule Diversity Set library identified ferristatin (NSC30611) as
an inhibitor of Tf-mediated iron uptake [43]. Ferristatin’s
mechanism of action includes down-regulation of TfR1 by a lipid
raft pathway that promotes receptor degradation [44]. Subsequent
analysis of structural orthologs determined similar properties were
associated with a second iron transport inhibitor NSC8679,
disodium 4-amino-3-((49-((2,4-diaminophenyl)azo)-4-biphenyly-
l)azo-5-hydroxy-6-(phenylazo)-2,7-naphthalene disulfonate [45].
In this report, we refer to the second compound as ferristatin II.
The influence of ferristatin II on Tf-mediated iron uptake was
characterized in vitro using HeLa cells. Dose-dependent inhibition
of cellular 55Fe uptake was observed when cells were treated with
up to 100 mM ferristatin II for 4 hours at 37uC in the presence of
55Fe-Tf (Figure 1A). The IC50 value of , 12 mM was similar to
previous results obtained for ferristatin [44]. Western blot analysis
confirmed that under these conditions, TfR1 was degraded
(Figure 1B). The dose-dependent loss of TfR1 correlates with
the reduction in iron uptake activity over this concentration range
and provides a molecular explanation for lower cellular 55Fe
uptake from Tf due to reduced receptor levels. Degradation of
TfR1 was time-dependent with approximately 60–70% of
receptors lost within 4 hours of treatment with 50 mM ferristatin
II (Figure 1C).
Ferristatin II does not Degrade TfR2 or HFE
TfR1 is known to associate with HFE at the plasma membrane
and during endocytosis [51,52]. It is thought that Tf binding to
TfR1 promotes dissociation of HFE from TfR1 and promotes its
Ferristatin II Promotes Degradation of TfR1
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interactions with TfR2, a close homolog of TfR1 [53]. To
investigate the specificity of ferristatin II, Hep3B cells stably
expressing TfR2 were treated with ferristatin II for 4 hours.
Although endogenous TfR1 was degraded, levels of TfR2 were not
decreased. (Figure 2A). It has been previously shown that
exogenous expression of epitope-tagged HFE can be used to
monitor its interaction with TfR1 [51,52]. Therefore HeLa cells
were transfected to transiently express flag-tagged HFE, then
treated with ferristatin II. Levels of flag-tagged HFE were
unaffected by ferristatin II while TfR1 was still degraded
(Figure 2B). These results show that ferristatin II selectively
induces the loss of TfR1.
Ferristatin II Induced Degradation of TfR1 is Sensitive to
Bafilomycin and Nystatin
It has been previously shown that ferristatin-induced TfR1
degradation is blocked by lysosomal inhibitors [44]. In a similar
fashion, bafilomycin A1, which raises the pH in intracellular
compartments, also blocks TfR1 degradation induced by
ferristatin (Figure 3A). These findings are consistent with the
idea that receptors are internalized for degradation. Past studies
with ferristatin also have shown that endocytosis through lipid
Figure 1. Ferristatin II induces degradation of TfR1 in vitro.
Panel A: HeLa cells were treated for 4 hours with indicated
concentrations of ferristatin II in the presence of 40 nM 55Fe-Tf. Shown
are means 6 SEM for triplicate values. Panel B: HeLa cell lysates were
collected for Western blotting to determine Tf receptor levels. Panel C:
Time course studies were carried out with cells treated with 50 mM
ferristatin II for up to 6 hours.
doi:10.1371/journal.pone.0070199.g001
Figure 2. Ferristatin II does not degrade TfR2 or HFE. Panel A:
Lysates from Hep3B cells stably expressing TfR2 were collected for
Western blotting after 4 hours of 50 mM ferristatin II treatment. Ratios
of band density for TfR1/Actin or TfR2/Actin are normalized to vehicle
control (DMSO) in the absence of ferristatin II. The bar graph
summarizes data from four separate experiments (n = 11 TfR1/Actin
p,0.001, determined by two-tailed Student’s t test, n = 12 TfR2/
Actin). Panel B: HeLa cells were transfected to express HFE-flag as
described in Materials and Method. Cells were then incubated 4 h
with or without 50 mM ferristatin II. Tubulin is shown as a loading
control and the indicated values were normalized to control lanes in
the absence of ferristatin II. The bar graph represents multiple
transfections (n = 8, p,0.001 for TfR1/Actin determined by two-tailed
Student’s t test).
doi:10.1371/journal.pone.0070199.g002
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raft domains was necessary for TfR1 degradation [44]. To
explore the possible role of lipid rafts in ferristatin II’s mechanism
of action, we used the cholesterol binding agent nystatin to
disrupt lipid rafts [54,55]. The effects of ferristatin II on TfR1
degradation were antagonized by the presence of nystatin
(Figure 3B).
TfR1 Domains Necessary for Clathrin Pathway
Interactions are not Necessary for Ferristatin II Induced
Degradation
Two ‘‘internalization defective’’ TfR1 mutants were studied.
Y20C/F23A TfR1 harbors point mutations within the receptor’s
endocytic motif, while D3–28 TfR1 is a deletion mutant lacking 25
amino acids of the domain [21]. This domain is responsible for
interaction with AP-2 and the clathrin machinery. Previous
investigations by McGraw and coworkers established stable
expression of these mutants in TRVb cells, which lack endogenous
Tf receptors [46]. Effects of ferristatin II on TRVb cells expressing
the Y20C/F23A or D3–28 TfR1 mutants were compared to
TRVb1 cells expressing wild-type TfR1 as a control (Figure 4A).
Both receptor mutants were degraded upon ferristatin II
treatment, although the time course of degradation was delayed
compared to wild-type TfR1 (Figure 4B).
Tf Blocks Ferristatin II Action
Since it is known that clathrin-mediated endocytosis of TfR1
occurs regardless of receptor occupancy [56,57,58], we examined
the effects of Tf on TfR1 degradation by ferristatin II. In the
presence of holo-Tf, the action of ferristatin II to induce
degradation of TfR1 was blocked (Figure 5). There are at least
two possible explanations for the observed antagonism: ferristatin
II competes with holo-Tf for binding to TfR1 or Tf acts as a non-
specific antagonist of ferristatin II action. Therefore, a receptor
point mutant, G647A TfR1, was constructed to probe the
receptor’s ligand-binding domain. Gly647 resides in the RGD
sequence previously shown to be critical for Tf binding [59,60].
The ability of ferristatin II to degrade wild type and G647A TfR1
was tested in TRVb cells. Transiently expressed G647A TfR1 was
distributed in these cells in a fashion similar to wild type as shown
by immunofluorescence microscopy (Figure 6A). As predicted, the
mutant receptor failed to bind 125I-labeled Tf (Figure 6B). Cells
transiently transfected to express either wild-type receptor or the
G647A mutant were treated with or without 50 mM ferristatin II
in the presence or absence of holo-Tf. Western blot analysis
confirmed that holo-Tf blocked ferristatin II induced degradation
of wild-type TfR1 but it did not interfere with G647A TfR1
degradation (Figure 6C). Therefore, binding of ligand to the
receptor blocks ferristatin II action.
Effects of Ferristatin II in vivo
To examine whether effects of ferristatin II observed in vitro
reflect its activity in vivo, rats were injected twice daily with vehicle,
0.2, 10 and 40 mg/kg of the drug for one or three days, then once
in the morning of the second or fourth day prior to tissue
collection. Monoacetylbenzidine, a known metabolite [61], was
detected in urine after 4 days of treatment at higher doses. Serum
ALT and AST activities were measured to assess possible liver
damage; serum ALT was slightly elevated at the highest dose but
AST was not significantly affected (Figure 7). These results
demonstrate the drug is metabolized by acetylation with minimal
toxicity over the time course and doses administered in our
experiments.
Significant changes in liver non-heme iron levels were not
observed over the course of ferristatin II treatment (Figure 7).
However, Tf saturation and serum iron levels were reduced after
2 days of treatment and significantly lower at all concentrations
tested for the 4 day treatments. Western blot analysis revealed
TfR1 levels were significantly reduced in livers from treated rats
compared to vehicle-injected controls, consistent with the action
of ferristatin II to degrade receptors in vitro (Figure 8A). It has
been proposed that dissociation of HFE from TfR1 promotes
synthesis of the iron regulatory hormone hepcidin [31,32].
Hepcidin then acts on the iron exporter ferroportin to reduce
systemic iron levels. qPCR analysis revealed that hepcidin
synthesis was enhanced in rats treated with ferristatin II with ,
9-fold increase in mRNA levels relative to control (vehicle-
injected) rats (Figure 8B). Reduced intestinal iron absorption was
also observed in rats treated with ferristatin II in uptake
experiments that determined the amount of 59Fe in blood after
intragastric gavage (Figure 8C).
Discussion
It has been long established that TfR1 enters cells through
clathrin-mediated endocytosis [6]. This pathway is particularly
well understood in the context of cellular iron delivery [62].
However, under some circumstances cell surface proteins like
epidermal growth factor receptor (EGFR) [63], the glucose
transporter GLUT4 [64] and TGF-b family members [65] are
internalized via lipid rafts in addition to clathrin dependent
mechanisms. Early observations with the first iron transport
inhibitor, ferristatin, indicated that like these other membrane
proteins, TfR1 could undergo lipid raft mediated internalization
[44]. Ferristatin induced degradation of TfR1 was sensitive to
Figure 3. Ferristatin II induced degradation is bafilomycin and
nystatin sensitive. Panel A: HeLa cells were treated overnight with
10 nM bafilomycin A1 prior to 4 h treatment with or without 50 mM
ferristatin II in the presence of 10 nM bafilomycin A1. Blot is
representative of several experiments. Panel B: HeLa cells were pre-
treated for 30 minutes with 25 mg/mL nystatin or left untreated. After
incubation, cells were treated with 50 mM ferristatin II for 4 hours.
Shown below are the density ratios for TfR1/Actin normalized to control
lanes (DMSO treated) in the absence of ferristatin II. Shown is a
representative blot from several similar experiments.
doi:10.1371/journal.pone.0070199.g003
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filipin and nystatin, two cholesterol-depleting drugs that implicate
a role for lipid rafts. Although nystatin-sensitivity has been noted
in some examples of clathrin-mediated endocytosis [66], knock-
down of clathrin did not interfere with TfR1 degradation induced
by ferristatin [44], further supporting the function of the lipid raft
pathway in the drug’s action. Our characterization of ferristatin
II activity reveals that this second member of the ferristatin family
of iron transport inhibitors induces degradation of TfR1 both
in vivo and in vitro. The loss of receptors explains why cells in
culture treated with ferristatin II have lower 55Fe uptake from Tf.
Our results further confirm sensitivity of the degradation pathway
to nystatin. Our studies of TRVb1 cells stably expressing various
receptor mutants defective in clathrin-mediated endocytosis [21]
suggest that elements of the TfR1 cytoplasmic domain necessary
for clathrin-mediated endocytosis may not be required for
ferristatin II-induced degradation. These independent lines of
evidence indicate that ferristatin II mediates degradation of TfR1
by a non-clathrin pathway, and a role for lipid rafts is suggested
by the sensitivity to cholesterol depletion.
The importance of lipid rafts in iron metabolism and signaling is
just beginning to be elucidated. For example, degradation of the
iron exporter ferroportin induced by the iron regulatory hormone
hepcidin is disrupted by cholesterol depletion [67] and ferroportin
has been shown to fractionate in detergent-resistant membrane
fractions with flotillin or caveolin-1, both markers of lipid rafts
[67]. Finally, the cholesterol binding protein CD133 is known to
influence Tf uptake in Caco-2 cells [68]. Such evidence suggests a
prominent role for lipid rafts in the regulation of iron metabolism.
Regulation of the lipid raft pathway by iron status provides an
additional layer in the complex regulation of iron transport. The
ability to pharmacologically induce an alternative TfR1 mem-
brane trafficking mechanism through lipid rafts provides an
Figure 4. Ferristatin induced degradation is independent of an interaction with the clathrin endocytic machinery. Panel A: TRVb cells
stably transfected to express WT TfR1, Y20C/F23A TfR1, or D3–28 TfR1 were treated for 4 hours with 50 mM ferristatin II. Density ratios for TfR1/Actin
normalized to control lanes (DMSO treated) in the absence of ferristatin II are indicated for each lane. Nonconsecutive lanes are separated by a white
space. Individual blots are separated by a black bar. All blots were probed using a sheep-TfR1 antibody raised against the ectodomain of TfR1. Panel
B: Time course of WT TfR1, Y20C/F23A TfR1 and D3–28 TfR1 degradation after 0–4 hour incubation with 50 mM ferristatin II. Shown are mean TfR1/
Actin ratios 6 SEM from 3 separate experiments performed in duplicate.
doi:10.1371/journal.pone.0070199.g004
Figure 5. Tf blocks ferristatin II induced receptor degradation.
HeLa cells were treated for 4 hours with 50 mM ferristatin II with or
without 1 mg/mL Tf. Shown below are the density ratios for TfR1/Actin
normalized to control lanes (DMSO treated) in the absence of ferristatin
II. Shown is a representative blot with similar results observed on
several separate occasions.
doi:10.1371/journal.pone.0070199.g005
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interesting new avenue to modulate the delivery of iron with
potential clinical application.
Unlike clathrin-mediated TfR1 endocytosis, which occurs
independent of receptor occupancy, the presence of Tf antag-
onizes ferristatin II-induced degradation. The finding that
G647A TfR1 with defective ligand binding is susceptible to
ferristatin II suggests that Tf may occlude the drug’s interactions
with wild-type TfR1. Alternatively, Tf interactions with the
receptor could induce conformational changes that block
ferristatin II binding to a distal domain, possibly including the
cytoplasmic domain. Further work is necessary to more precisely
define structural elements of TfR1 that contribute to targeting by
ferristatin II. Our results indicate these effects are quite specific
since ferristatin II does not affect protein levels of TfR2
expressed in Hep3B cells. Although structurally related, TfR1
and TfR2 differ in domain interactions with both HFE and Tf
[47]. Sensitivity to degradation by ferristatin II marks another
structural distinction between the two receptors that should be
further explored.
The ability of ferristatin II to reduce TfR1 levels in vivo was
confirmed by administering the drug to rats at doses up to 40 mg/
kg. Serum iron and transferrin saturation were lowered after 2
days of treatment, and significantly reduced at all concentrations
of ferristatin II tested after 4 days of treatment. These effects were
associated with a ,50% decrease in the protein level of TfR1 in
liver. Notably, hepatic non-heme iron content did not change. The
lack of change in hepatic iron despite hypoferremia is consistent
with a block in iron mobilization. Our intragastric gavage
experiments show that rats treated with ferristatin II also have
reduced intestinal uptake of 59Fe to the blood. Both of these
observations can be explained by the observed up-regulation of
hepcidin, a regulatory hormone of iron metabolism [38]. Hepcidin
interacts with the iron exporter ferroportin to induce its lysosomal
degradation, thereby blocking dietary absorption [35] and release
of iron stores [69]. Hepcidin is known to be induced by increasing
Tf saturation under high iron conditions which triggers dissoci-
ation of HFE from TfR1 [31] coupled to its association with
stabilized TfR2 [32]. Since ferristatin II degrades TfR1 but not
HFE, we hypothesize the action of ferristatin II releases HFE to
promote hepcidin synthesis. In this scenario, receptor degradation
rather than high iron promotes HFE association with TfR2, and
possibly activates other factors that regulate hepcidin expression
[70,71]. As shown in Figure 9, under basal conditions, HFE is
bound to TfR1. As levels of iron saturated Tf increase, Tf out-
competes HFE for binding to TfR1. Released HFE can bind TfR2
to initiate a signaling cascade promoting hepcidin synthesis. In the
presence of ferristatin II, the degradation of TfR1 liberates HFE to
bind TfR2 and induce hepcidin synthesis in the liver. This action
appears to be independent of high iron, since rats treated with
ferristatin II display hypoferremia yet continue to upregulate
hepcidin synthesis.
It is important to consider that other targets of ferristatin II
action may contribute to the effects we observe. In vitro studies
have shown that ferristatin II also inhibits transport of iron by
DMT1 [45], and this transporter plays an important role in apical
iron uptake by enterocytes [72,73]. Inhibition of DMT1 activity
would reduce iron absorption, leading to lower serum iron and
transferrin saturation independent of hepcidin’s action on
ferroportin. On the other hand, some reports have suggested that
hepcidin also regulates DMT1 function in the intestine [74], so
that direct suppression of DMT1 might also arise due to hepcidin
induction by ferristatin II. Regardless of the precise target(s),
inhibition of import and/or export of iron across the intestinal
mucosa provides a rational explanation for the reduced level of
circulating iron observed in rats treated with ferristatin II. The
idea that increased hepcidin blocks iron mobilization from stores,
a known action of the hormone (67), is also consistent with the
observation that non-heme iron levels in liver are not altered by
ferristatin II treatment.
Several other pharmacological tools now have been developed
to target the hepcidin axis [75], including ‘‘mini-hepcidins’’ that
down-regulate ferroportin [76,77], BMP inhibitors that block
Smad signaling [78,79], and agents that perturb Stat signaling
Figure 6. Ferristatin II induces degradation of ligand binding
mutant G647A TfR1. Panel A: TRVb cells were transfected with 1 mg
WT TfR1 or G647A TfR1, plated on poly-L-lysine coated cover slips and
fixed with 4% paraformaldehyde. Cells were immunoreacted with OKT9
(a-TfR1) followed by goat anti-mouse Alexa 488 and imaged using a
Zeiss Observer Z1 Axioscope microscope. Panel B: TRVb cells were
transfected as in (A) in 6-well plates and incubated for 48 hours (see
Experimental Procedures for details). Cells were then chilled, washed
and incubated with 500 nM 125I-Tf in the absence or presence of 5 mM
unlabeled Tf for 2 hours. After washing and lysis, cell associated
radioactivity was measured by c-counting. Absolute deviation for
duplicate values for cells with 500 nM 125I-Tf (open bars) or 500 nM 125I-
Tf +5 mM Tf (closed bars) is shown. Inset: Western blot confirms
equivalent expression levels for WT and G647A TfR1. Panel C: TRVb cells,
transfected with WT or G647A TfR1 were treated for 4 hours with 50 mM
ferristatin II with or without 1 mg/mL Tf. Shown below are the density
ratios for TfR1/Actin normalized to control lanes (DMSO treated) in the
absence of ferristatin II. Nonconsecutive lanes are separated by a white
space. Blot is representative of several experiments (n = 6, WT and
G647A TfR1).
doi:10.1371/journal.pone.0070199.g006
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Figure 7. Effects of ferristatin ll in vivo. Rats were treated with vehicle control (saline) or 0.2, 10 or 40 mg/kg ferristatin ll for 2 or 4 days as
described in Experimental Procedures. Shown are mean values 6 SEM (n= 4) for body weight (*P = 0.022), liver non-heme iron, Tf saturation
(*P = 0.018, 0.002 and 0.006 for 0.2, 10 and 40 mg/kg, respectively) and serum iron levels (*P = 0.016, 0.002 and 0.005 for 0.2, 10 and 40 mg/kg,
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[80,81]. The ferristatins are unique in targeting TfR1 degradation
[43,44]. We previously have shown that degradation of the
receptor induced by ferristatin occurs through a lipid raft-
dependent mechanism [44]. Recently, the antimalarial agent
dihydroartemisinin was shown to degrade TfR1 [82]. Depletion of
cellular iron through this mechanism was proposed to account for
this drug’s anticancer effects. Interestingly, down-regulation of
TfR1 by dihydroartemisinin also was shown to proceed via a lipid
raft mechanism. The alternative TfR1 membrane trafficking
mechanism revealed by use of small molecule inhibitors provides
an intriguing new pathway to potentially regulate iron metabolism
in a number of different disease states.
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Figure 8. Ferristatin II alters iron homeostasis in vivo. Panel A: Liver lysates from rats injected with saline or 40 mg/kg ferristatin ll for 4 days
were immunoblotted to determine TfR1 levels. Actin was used as a loading control. Bar graph shows normalized TfR1/actin ratio as the mean 6 SEM
(n = 7; *P,0.001 determined by two-tailed Student’s t test). Panel B: Liver RNA was isolated, reverse transcribed and qPCR performed as described
under Experimental Procedures. Data were normalized to levels of 36B4. Shown are means 6 SEM (n= 5–7; *P,0.001 determined by two-tailed
Student’s t test). Panel C: To determine intestinal iron absorption, control and treated rats were fasted for 4 h and 59Fe was administered by gavage.
Blood samples were drawn at indicated times and radioactivity was determined by gamma counting. Shown are means 6 SEM for control (open
circles; n = 4–6) and ferristatin ll (closed circles; n = 7–8; *P = 0.01 and **P= 0.05 determined by two-tailed Student’s t test).
doi:10.1371/journal.pone.0070199.g008
respectively) measured after a 6 h fasting period. P values were determined by one-way ANOVA followed by Tukey’s test as a post hoc comparison.
Monoacetylbenzidine (MAB) levels in rat urine were determined by HPLC and normalized to creatinine levels (arbitrary units). Shown are means 6
SEM (AU= arbitrary units; ND=not detected. Serum ALT and AST activities were determined using ALT and AST reagents (Thermo Scientific) for rats
injected for 4 days with vehicle or 40 mg/kg ferristatin II. Shown are means 6 SEM (n= 3–6; *P = 0.033 determined by two-tailed Student’s t test).
doi:10.1371/journal.pone.0070199.g007
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